Backed by Amgen’s four decades of biologics expertise, our high-quality biosimilars can potentially offer more affordable, life-altering treatment options that contribute to the sustainability of our healthcare system and allow for greater investment in new medicines for patients.1
Amgen has one of the largest stakes for biosimilars in the industry. As we continue to launch biosimilars over the coming years, we believe that they will bring meaningful cost savings to patients and the healthcare system.
By the Numbers:
- 11 medicines in our portfolio in inflammation and cancer
- Invested more than $2 billion across the development of biosimilar medicines
- 3 biosimilar medicines listed on the World Health Organization’s Model List of Essential Medicines
- IQVIA (2018). The Impact of Biosimilar Competition in Europe. PDF file. Retrieved from: https://www.medicinesforeurope.com/wp-content/uploads/2017/05/IMS-Biosimilar-2017_V9.pdf